This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
They estimate that the number of people aged 65 years and older is expected to increase from 35 million in 2000 to 71 million in 2030. million in 2030. Globally, the number of older adults (aged 65 years and older) is projected to increase even more dramatically — more than doubling from 420 million in 2000 to 973 million in 2030.
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinicaltrials for the purposes of novel drug development. from 2020 to 2030 and generate revenue of $151.7 billion in 2030. 2 Pain 1994 Apr;57(1):5-15. 3 Psychol Res Behav Manag.
DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Market Size, Forecast, Insights, and Competitive Landscape” report has been added to ResearchAndMarkets.com’s offering. Read More
Deletion Syndrome – Global Market Insights, Epidemiology and Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. deletion syndrome in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030. Country-Wise Epidemiology.
DUBLIN–(BUSINESS WIRE)–The “Global Cannabis Market- Market Size & Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The global cannabis market in the COVID-19 period has been estimated to value USD 25,650.4 million by 2030 at a CAGR of 23.9%, 2021-2030.
According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated.
DUBLIN–(BUSINESS WIRE)–The “Skin Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering. Cannabis Science Inc. The global skin cancer drugs market is expected to grow from $1.44 billion in 2020 to $1.61 GlaxoSmithKline PLC.
billion by 2030, growing at a CAGR of 8.4% from 2021 to 2030. Genomics test results allow practitioners and patients to set individualized, trackable goals around pharmacogenomics (PGx), cannabis DNA, nutrition DNA, and fitness DNA for personalized health and wellness. billion (2020).
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content